Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin: 2021-2024

Historic EBT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to -8.54%.

  • Kiniksa Pharmaceuticals International's EBT Margin rose 2143.00% to 15.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.13%, marking a year-over-year increase of 3188.00%. This contributed to the annual value of -8.54% for FY2024, which is 2518.00% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's EBT Margin stood at -8.54%, which was up 74.67% from -33.72% recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBT Margin peaked at 950.93% during FY2022, and registered a low of -426.22% during FY2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median EBT Margin value was -8.54% (recorded in 2024), while the average stood at 302.89%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 137,715bps in 2022, then crashed by 98,465bps in 2023.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's EBT Margin stood at -426.22% in 2021, then spiked by 137,715bps to 950.93% in 2022, then slumped by 98,465bps to -33.72% in 2023, then surged by 2,518bps to -8.54% in 2024.